Tag: #Biotech
-
Lilly & Novo Nordisk Reach Landmark Pricing Agreement with U.S. Government on Obesity Drugs
As the battle for dominance in obesity treatment intensifies, Eli Lilly and Novo Nordisk are racing ahead with groundbreaking drugs. But with politics and market power in play, the story goes far beyond science — it’s shaping the future of healthcare itself.
-
America’s 100% Drug Import Tariff — Reshaping Pharma, Patents and Patients
On September 25, 2025, the White House announced a 100% tariff on imported branded and patented drugs. This policy aims to push pharmaceutical manufacturing back to the U.S. while sparking debate among domestic firms, foreign drugmakers, and patient advocates about costs, supply, and innovation.
-
FDA and HHS Announce Biosimilar Reform — No More Comparative Trials, Full Interchangeability Ahead
The U.S. FDA and HHS have announced a landmark reform to eliminate comparative efficacy trials for biosimilars, aiming to reduce development costs and expand patient access to affordable biologic medicines.